Globeflex Capital L P purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 108,569 shares of the specialty pharmaceutical company's stock, valued at approximately $8,987,000. ANI Pharmaceuticals makes up about 1.1% of Globeflex Capital L P's investment portfolio, making the stock its 17th biggest holding. Globeflex Capital L P owned 0.48% of ANI Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Arrowstreet Capital Limited Partnership purchased a new position in ANI Pharmaceuticals during the third quarter valued at approximately $32,992,000. Deutsche Bank AG purchased a new stake in ANI Pharmaceuticals in the 2nd quarter worth approximately $26,775,000. Balyasny Asset Management L.P. lifted its position in ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock worth $26,211,000 after buying an additional 276,233 shares in the last quarter. William Blair Investment Management LLC acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $21,372,000. Finally, Rubric Capital Management LP boosted its stake in shares of ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock valued at $16,813,000 after buying an additional 200,998 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Thomas Haughey sold 2,000 shares of the company's stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares in the company, valued at approximately $3,144,452.64. This represents a 4.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the transaction, the chief financial officer directly owned 174,693 shares in the company, valued at approximately $14,213,022.48. This represents a 1.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 18,987 shares of company stock worth $1,546,405. Insiders own 8.10% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ANIP. Guggenheim dropped their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Zacks Research cut ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Wall Street Zen downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Weiss Ratings lowered ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group cut their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research note on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $105.83.

View Our Latest Report on ANIP

ANI Pharmaceuticals Price Performance

ANIP stock opened at $75.35 on Monday. The firm has a market cap of $1.73 billion, a PE ratio of 16.24 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The company has a fifty day simple moving average of $80.36 and a 200 day simple moving average of $78.88. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same period in the prior year, the business posted $1.80 earnings per share. The business's quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

(Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Read More

• Five stocks we like better than ANI Pharmaceuticals
• VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
• 3 Closed-End Funds to Maximize Dividend Payments
• Rocket Lab's Sell-Off Is Fading—Is It Finally Safe to Buy?
• $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ANI Pharmaceuticals Right Now?

Before you consider ANI Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.

While ANI Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here